These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9867151

  • 21. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE, Lewis MR, Bebb GG, Clarke KG, Odom-Maryon TL, Shively JE, Raubitschek AA.
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [Abstract] [Full Text] [Related]

  • 22. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
    DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S.
    Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
    [Abstract] [Full Text] [Related]

  • 23. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
    Li M, Meares CF, Zhong GR, Miers L, Xiong CY, DeNardo SJ.
    Bioconjug Chem; 1994 Sep; 5(2):101-4. PubMed ID: 8031871
    [Abstract] [Full Text] [Related]

  • 24. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1998 Sep; 9(6):773-82. PubMed ID: 9815172
    [Abstract] [Full Text] [Related]

  • 25. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
    O'Donnell RT, Leigh BR, Christensen SD, Goldstein DS, Kukis DL, Shen S, Yuan A, DeNardo DA, Kroger LA, DeNardo GL.
    Cancer Biother Radiopharm; 1999 Jun; 14(3):167-76. PubMed ID: 10850301
    [Abstract] [Full Text] [Related]

  • 26. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
    Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, Bombardieri E, Martin F, Giussani A, Figini M, Canevari S.
    Cancer Immunol Immunother; 2005 Dec; 54(12):1200-13. PubMed ID: 15926078
    [Abstract] [Full Text] [Related]

  • 30. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics.
    Chong HS, Garmestani K, Ma D, Milenic DE, Overstreet T, Brechbiel MW.
    J Med Chem; 2002 Aug 01; 45(16):3458-64. PubMed ID: 12139456
    [Abstract] [Full Text] [Related]

  • 31. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
    DeNardo GL, Kroger LA, DeNardo SJ, Miers LA, Salako Q, Kukis DL, Fand I, Shen S, Renn O, Meares CF.
    Cancer; 1994 Feb 01; 73(3 Suppl):1012-22. PubMed ID: 8306243
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, Renn O, Greiner DP, Kukis DL, Kronenberger SI.
    Cancer Res; 1994 Nov 15; 54(22):5937-46. PubMed ID: 7954426
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
    Li M, Meares CF, Salako Q, Kukis DL, Zhong GR, Miers L, DeNardo SJ.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Formation kinetics and stability studies on the lanthanide complexes of 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid by capillary electrophoresis.
    Zhu X, Lever SZ.
    Electrophoresis; 2002 May 01; 23(9):1348-56. PubMed ID: 12007137
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.